Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, 00161 Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Cell Rep. 2020 Feb 11;30(6):1735-1752.e7. doi: 10.1016/j.celrep.2020.01.024.
The antidiabetic drug phenformin displays potent anticancer activity in different tumors, but its mechanism of action remains elusive. Using Shh medulloblastoma as model, we show here that at clinically relevant concentrations, phenformin elicits a significant therapeutic effect through a redox-dependent but complex I-independent mechanism. Phenformin inhibits mitochondrial glycerophosphate dehydrogenase (mGPD), a component of the glycerophosphate shuttle, and causes elevations of intracellular NADH content. Inhibition of mGPD mimics phenformin action and promotes an association between corepressor CtBP2 and Gli1, thereby inhibiting Hh transcriptional output and tumor growth. Because ablation of CtBP2 abrogates the therapeutic effect of phenformin in mice, these data illustrate a biguanide-mediated redox/corepressor interplay, which may represent a relevant target for tumor therapy.
降糖药苯乙双胍在不同肿瘤中显示出强大的抗癌活性,但作用机制仍不清楚。在这里,我们使用 Shh 髓母细胞瘤作为模型,表明在临床相关浓度下,苯乙双胍通过一种依赖于氧化还原但不依赖于复合物 I 的机制产生显著的治疗效果。苯乙双胍抑制线粒体甘油磷酸脱氢酶(mGPD),一种甘油磷酸穿梭的组成部分,并导致细胞内 NADH 含量升高。mGPD 的抑制模拟了苯乙双胍的作用,并促进了共抑制因子 CtBP2 和 Gli1 之间的结合,从而抑制了 Hh 转录输出和肿瘤生长。因为 CtBP2 的缺失消除了苯乙双胍在小鼠中的治疗效果,这些数据说明了一种双胍类药物介导的氧化还原/共抑制因子相互作用,这可能是肿瘤治疗的一个相关靶点。